Answers are grounded in this paper and cite their sources.
3057 Background: Predictive biomarkers for immune checkpoint inhibitors, such as PD-L1 (CD274) copy number, PD-L1 expression and tumor mutational burden (TMB), have not been widely studied in metastatic breast cancer (mBC). Methods: FFPE samples from 84 cases of BC, 71 ductal (IDC) and 13 lobular (ILC), were immunostained (IHC) using rabbit monoclonal PD-L1/CD274 (SP142). Membranous PD-L1 staining was scored as negative, low positive (1 – 24%) and high positive ( = or > 25%) for both tumor cells and tumor infiltrating lymphocytes (TILs). Comprehensive genomic profiling (CGP) was used to measure PD-L1gene amplification and total TMB, calculated by counting mutations across a 1.25Mb region spanning 315 genes. TMB was also calculated for a separate cohort of 6,751 metastatic BC (mBC). Results: PD-L1 immunoreactivity was noted as low positive in 4/84 (5%) BC [2 tumor+/TIL+ and 2 tumor+/TIL-], and as low positive in the TIL component for 5 (6%) additional BC [tumor-/TIL+]; all 9 (100%) were IDCs. No PD-L1 immunoreactivity was noted in the TIL component of the remaining cases, despite the presence of prominent TILs in most cases. PD-L1 protein expression correlated with decreased overall survival (OS) [100% PD-L1+ cases and 0% tumor-/TIL+ cases expired, (p = 0.002)], while showing a trend toward correlation with tumors that did not recur [100% PD-L1+ cases and 100% tumor-/TIL+ did not recur, (p = 0.08)] and age at diagnosis in the ER+ subgroup [100% PD-L1+ cases diagnosed at a peri-menopausal age and 100% tumor-/TIL+ cases diagnosed at a post-menopausal age, (p = 0.069)]. On multivariate analysis, tumor grade (p = 0.025) and disease recurrence independently predicted OS. PD-L1gene amplification was identified in only 57 (0.1%) of 6,751 mBC. High TMB, defined as greater than the top quartile across all indications, was found in 1,351 of 6,643 (20%) mBC cases. Conclusions: PD-L1 expression is found in both cancer cells and TILs and is a significant adverse prognostic factor in BC. PD-L1 amplification is extremely uncommon, whereas high TMB was found in 20% of mBC. The potential for these biomarkers to identify BC patients as candidates for immunotherapy warrants further study.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: